NEW YORK--(BUSINESS WIRE)--Acuamark Diagnostics, Inc., a biotechnology company that uses a unique approach to develop cost-effective blood-based screening tests for the early detection of cancer, today announced the addition of Brian C. Carr to its Board of Directors.
Mr. Carr is a seasoned industry executive with almost thirty years of experience in the diagnostic laboratory industry. He has also been involved in several early stage biotechnology companies focused on advancing precision medicine and on improving early disease detection.
